UCB
A biopharmaceutical company focused on severe diseases in neurology and immunology.
UCB | BR
Overview
Corporate Details
- ISIN(s):
- BE0002730118 (+5 more)
- LEI:
- 2138008J191VLSGY5A09
- Country:
- Belgium
- Address:
- ALLÉE DE LA RECHERCHE 60, 1070 ANDERLECHT
- Website:
- https://www.ucb.com/
- Sector:
- Manufacturing
Description
UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-14 00:00 |
250314 - Acquisition of own shares_ENG.pdf
|
English | PDF • 229.1 KB | ||
| 2025-03-14 00:00 |
250314 - Acquisition actions propres_FR.pdf
|
French | PDF • 229.1 KB | ||
| 2025-03-14 00:00 |
250314 - Verwerving van eigen aandelen_NL.pdf
|
Dutch | PDF • 228.2 KB | ||
| 2025-03-12 20:00 |
EN 250312 - PR Transparency notification BlackRock.pdf
|
English | PDF • 291.0 KB | ||
| 2025-03-12 20:00 |
FR 250312- CdP Notification de transparence BlackRock.pdf
|
French | PDF • 292.4 KB | ||
| 2025-03-12 20:00 |
NL 250312 - PB Transparantieverklaring BlackRock.pdf
|
Dutch | PDF • 297.7 KB | ||
| 2025-03-11 20:00 |
EN 250311 transparency notification PR BR.pdf
|
English | PDF • 291.3 KB | ||
| 2025-03-11 20:00 |
FR 250311 notification de transparence PR BR.pdf
|
French | PDF • 292.5 KB | ||
| 2025-03-11 20:00 |
NL 250311 transparencieverklaring PR BR.pdf
|
Dutch | PDF • 299.0 KB | ||
| 2025-03-11 00:00 |
EN 250311 transparency notification PR BR.pdf
|
English | PDF • 291.3 KB | ||
| 2025-03-11 00:00 |
FR 250311 notification de transparence PR BR.pdf
|
French | PDF • 292.5 KB | ||
| 2025-03-11 00:00 |
NL 250311 transparencieverklaring PR BR.pdf
|
Dutch | PDF • 299.0 KB | ||
| 2025-02-27 00:00 |
UCB PR FY 2024 Feb 27 2025 ENG.pdf
|
English | PDF • 602.5 KB | ||
| 2025-02-27 00:00 |
UCB PR FY 2024 Feb 27 2025 FR.pdf
|
French | PDF • 575.0 KB | ||
| 2025-02-27 00:00 |
UCB PR FY 2024 Feb 27 2025 NL.pdf
|
Dutch | PDF • 570.3 KB |
Automate Your Workflow. Get a real-time feed of all UCB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for UCB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for UCB via our API.
Peer Companies
